

Tocilizumab Guided Questionnaire Stroke

AER:	Local Case ID:						
Site No:	Patient Date of Birth						
	(dd-MMM-yyyy):						
Patient ID/Initials:	Patient Gender: M F						
Patient Weight	Patient Height						
Stroke has been observed in some pat							
By filling in this questionnaire, you will help us to understand more fully the risk factors for this condition.							
Reporter Information							
Name of reporter completing this form:							
(if other than addressee, provide contact information below)							
Health Care Provider?							
Phone Number: Fax Num	Phone Number: Fax Number: Email Address:						
Reported Term							
Description of the event							
Type of Stroke: Schemic:							
Hemorrhagic							
Other/unknown—please spo	<u> </u>						
Hospital Admission							
Onset Date (MM/DD/YYYY)							
Stop Date (MM/DD/YYYY)							
Select all that apply:							
SERIOUSNESS CRITERIA CLASSIFICATION							
☐ Death Date of Death (MM/DD/YYYY) ☐ Life-Threatening (use only if patient was at immediate risk of death due to event)							
☐ Initial/Prolonged Hospitalization							
☐ Congenital Anomaly/Birth Defect							

☐ Persistent or Significant Disability ☐ Medically Significant (important medical events that may jeopardize the patient and may require medical/surgical intervention to prevent the other outcomes) ☐ Non-Serious							
Related to Tocilizumab?	☐ Yes	☐ No					
()Litcome of the event:	•	oroved known	☐Recovered with sequelae ☐Worsened ☐Death				
Drug therapy details - Tocilizumab							
Indication:							
Start Date (MM/DD/YYYY)							
Starting Dose	mg/	′kg	Total monthly dose (mg)				
Route							
Frequency	☐ Monthly		Other, please specify:				
History of 4 most recent Infusions prior to Adverse Event (AE)	Date (MM/DD/YYYY) Dose		Other, please specify: Action Taken in response to AE? Dose maintained Dose decreased Dose interrupted Dose increased Dose discontinued Dose maintained Dose decreased Dose interrupted Dose increased Dose increased Dose discontinued Dose maintained Dose decreased Dose decreased Dose interrupted Dose interrupted Dose increased Dose increased Dose discontinued Dose discontinued Dose maintained Dose maintained Dose decreased Dose interrupted Dose interrupted Dose interrupted Dose increased Dose increased				

Treatment for the e	vent						
What treatment was in	itiated for the e	event? (including an	y pre-h	ospitalizatior	n treatment)		
Treatment		Dosing Regime	n	Dates of Therapy (MM/DD/YYYY to MM/DD/YYYY)			
Please attach all labimaging tests. Pleareported. Labs Attached	se provide (SI (International	Syster	n of Units)	if availab		
Please indicate if any o	of the following	tests have been pe	erformed	d, and the re	sult:	т	Г
	Baseline Value (Prior to TCZ Use)	Date of Baseline Test (MM/DD/YYYY)		of Test DD/YYYY)	Test Results (include units)	Reference Range (If Applicable)	Pending
CT Scan							☐ Yes
MRI							Yes
Carotid Doppler							Yes
MRA (Magnetic Resonance Angiogram)							☐ Yes
Cerebral Arteriogram							Yes
Other							☐ Yes
Please specify:							
		1	1		1		
Risk Factors							
Please indicate if the fo	ollowing conditi	ions are either part	of the p	atient's med	lical history	or are still activ	е
Prior Stroke		☐History		Concurrent		Not present	
Specify:							
Prior TIA		☐History		Concurrent		Not present	
Specify:			_			,	
Prior Heart Attack Specify:		History	ПС	Concurrent		Not present	
Hypertension		History		Concurrent		Not present	

Smoking Specify:		□History	,	Concurrent	☐Not present
Diabetes Mellitus		History	1	Concurrent	☐Not present
Coronary artery Disease Specify:		□History	,	Concurrent	□Not present
Atrial Fibrillation		☐History	,	Concurrent	☐Not present
Sickle Cell Anemia	ickle Cell Anemia		,	Concurrent	☐Not present
Hypercholesterolemia		☐History		Concurrent	☐Not present
Physical Inactivity		☐History	,	Concurrent	☐Not present
Obesity		☐History	,	Concurrent	☐Not present
Low platelet count	,		,	Concurrent	☐Not present
Cardiac valvular disease		☐History	,	Concurrent	☐Not present
Other		☐History	,	Concurrent	☐Not present
Please specify:					
Past/Concomitant I	viedication	15			
☐ Medication List A	Attached				
■ Medication List A	Attached	Dose	Route	Frequency	Past, Concomitant, or N/A
Medication List A	Attached Yes No	Dose	Route	Frequency	Past, Concomitant, or N/A Past Concomitant N/A
	Yes	Dose	Route	Frequency	
Methotrexate Other DMARDs	☐ Yes ☐ No ☐ Yes	Dose	Route	Frequency	☐Past ☐Concomitant ☐N/A
Methotrexate Other DMARDs Specify: Biologic DMARDs	☐ Yes ☐ No ☐ Yes ☐ No ☐ Yes ☐ Yes	Dose	Route	Frequency	☐Past ☐Concomitant ☐N/A ☐Past ☐Concomitant ☐N/A
Methotrexate Other DMARDs Specify: Biologic DMARDs Specify: Corticosteroids Specify: Lipid lowering Medications	☐ Yes ☐ No ☐ Yes ☐ Yes	Dose	Route	Frequency	□ Past □ Concomitant □ N/A □ Past □ Concomitant □ N/A □ Past □ Concomitant □ N/A
Methotrexate Other DMARDs Specify: Biologic DMARDs Specify: Corticosteroids Specify: Lipid lowering Medications Specify: Antihypertensive medications	☐ Yes ☐ No ☐ Yes ☐ Yes	Dose	Route	Frequency	□ Past □ Concomitant □ N/A
Methotrexate Other DMARDs Specify: Biologic DMARDs Specify: Corticosteroids Specify: Lipid lowering Medications Specify: Antihypertensive	Yes No	Dose	Route	Frequency	□Past □Concomitant □N/A □Past □Concomitant □N/A □Past □Concomitant □N/A □Past □Concomitant □N/A □Past □Concomitant □N/A

there have been any significant changes from the initial report.					
Thank you for completing this for	rm.				
Completed by:					
Name:	Position:				
Signature:	Date:				
E-mail:					

Version 1.0, Effective Date: 18-June-2012